Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status

Jihye Choi 1,2, Chan Sub Park 1, Min-Ki Seong 1, Hyesil Seol 3, Jae-Sung Kim 4, In-Chul Park 4, Woo Chul Noh 1, Hyun-Ah Kim 1

1Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
2Department of Surgery, National Medical Center, Seoul, Korea
3Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
4Division of Basic Radiation Bioscience, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

ABSTRACT

Purpose: Phosphorylated ribosomal S6 kinase 1 (pS6K1) is a major downstream regulator of the mammalian target of rapamycin (mTOR) pathway. Recent studies have addressed the role of S6K1 in adipogenesis. pS6K1 may affect the outcome of estrogen depletion therapy in patients with hormone-sensitive breast cancer due to its association with adipogenesis and increased local estrogen levels. This study aimed to investigate the potential of pS6K1 as a predictive marker of adjuvant aromatase inhibitor (AI) therapy outcome in postmenopausal or ovarian function-suppressed patients with hormone-sensitive breast cancer.

Methods: Medical records were retrospectively reviewed in postmenopausal or ovarian function-suppressed patients with estrogen receptor-positive and node-positive primary breast cancer. pS6K1 expression status was scored on a scale from 0 (negative) to 3+ (positive) based on immunohistochemical analysis.

Results: A total of 428 patients were eligible. The median follow-up duration was 44 months (range, 1–90). In patients with positive pS6K1 expression, AIs significantly improved disease-free survival (DFS) compared to selective estrogen receptor modulators (SERMs) (5 year-DFS: 83.5% vs. 50.7%, \( p = 0.016 \)). However, there was no benefit of AIs on DFS in the pS6K1 negative group (5 year-DFS 87.6% vs. 91.4%, \( p = 0.630 \)). On multivariate analysis, AI therapy remained a significant predictor for DFS in the pS6K1 positive group (hazard ratio, 0.39; 95% confidence interval, 0.16–0.96; \( p = 0.041 \)). pS6K1 was more effective in predicting the benefit of AI therapy in patients with ages < 50 (\( p = 0.021 \)) compared to those with ages ≥ 50 (\( p = 0.188 \)).

Conclusion: pS6K1 expression may predict AI therapy outcomes and serve as a potential predictive marker for adjuvant endocrine therapy in postmenopausal and ovarian function-suppressed patients with hormone-sensitive breast cancer. AIs may be more effective in patients with pS6K1 positive tumors, while SERM could be considered an alternative option for patients with pS6K1 negative tumors.

Keywords: Aromatase inhibitors; Biomarkers, tumor; Breast neoplasms; Ribosomal protein S6 kinase, 70kD, polypeptide 1; Tamoxifen
INTRODUCTION

Adjuvant endocrine therapy is an important treatment option for patients with hormone-sensitive breast cancer [1]. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) form the backbone of adjuvant endocrine therapy. The SERM tamoxifen is a competitive agonist of the estrogen receptor (ER) and has been the standard drug used for adjuvant endocrine therapy for decades, in both premenopausal and menopausal women. In contrast, AIs deplete estrogen by directly inhibiting aromatase, thereby stopping estrogen biosynthesis in the extra-gonadal organs, including the adrenal glands, liver, bones, and particularly, the adipose tissue [2]. AIs are contraindicated for stand-alone therapy in premenopausal women as they stimulate estrogen production in the ovaries. Ovarian function suppression is, therefore, a prerequisite for AI therapy in premenopausal women. However, in postmenopausal women, current guidelines recommend third-generation AIs instead of tamoxifen as the gold standard treatment, due to lower recurrence rates and better disease-free survival (DFS) [3-5].

Despite the notably higher efficacy of AIs, their use is associated with numerous adverse effects including musculoskeletal pain, osteoporosis, and increased cardiovascular events. These lead to gradually decreasing compliance rates and in the long-term, to non-breast cancer related deaths [5,6]. Consequently, guidelines recommend the use of SERMs instead of AIs in patients with contraindications or intolerance to AIs due to the concern that the adverse effects of AI may outweigh its survival benefits in those patients [4]. Therefore, there is a high demand for a novel biomarker that predicts the desired survival benefits while avoiding unwanted side effects. However, despite substantial advances in the molecular profiling of breast cancer during the last few decades, there are currently no established predictive biomarkers for individualized adjuvant endocrine regimens, other than the ER.

Phosphorylated ribosomal S6 kinase 1 (pS6K1) is known to be a key driver of the mammalian target of rapamycin (mTOR) pathway and overexpression of S6K1 has been associated with poor prognosis in breast cancer [7,8]. Interestingly, pS6K1 has recently been shown to play a role in early adipocyte differentiation (adipogenesis) in preclinical models [9-11]. Adipocytes are closely related to hormone-sensitive breast cancer development and prognosis, by contributing to increased local estrogen production [12,13]. These results provide a theoretical link between pS6K1, adipogenesis, and local estradiol levels, which are associated with the prognosis of breast cancer. This suggests that patients with tumors expressing pS6K1 could obtain greater survival benefits from estrogen-depleting AIs than from SERMs. As such, in this study, we evaluated the potential of pS6K1 as a predictive marker for adjuvant AI therapy in postmenopausal or ovarian function suppressed patients with hormone-sensitive breast cancer.

METHODS

Study design and patient selection
A total of 2,663 patients with primary breast cancer who underwent surgical treatment between March 2008 and May 2015 were included in the study. Among them, 428 women with postmenopausal (n = 401) or ovarian function-suppressed (n = 17) estrogen receptor-positive and node-positive breast cancer and who had received adjuvant endocrine therapy...
were identified and selected for further analysis. Premenopausal women who underwent bilateral oophorectomy during adjuvant endocrine therapy were also included in this analysis (n = 10). Gonadotropin-releasing hormone agonists were administered monthly for a minimum of 2 years for suppression of ovarian function. Letrozole, anastrozole, or exemestane had been used as components of upfront, switch, or extended adjuvant endocrine therapy regimens. For the purposes of this study, patients who were treated with AIs at any point during their course of adjuvant endocrine therapy were defined as AI-treated patients. All patients in the cohort received treatment after providing informed consent, in accordance with the principles of the Declaration of Helsinki. The need for informed consent for using patient medical records was waived owing to the retrospective nature of this study.

Medical records were retrospectively reviewed to obtain clinicopathologic information regarding age, body mass index (BMI), tumor size (≤ 2 cm vs. > 2 cm), nodal (N) stage (N1 vs. N2–3), progesterone receptor (PR) status, human epidermal growth factor receptor (HER)-2 status, histologic grade, history of previous chemotherapy, types of surgery, and pS6K1 status. The Institutional Review Board of the Korean Cancer Center Hospital approved the protocol version 3.0 (K-1707-002-015).

**Immunohistochemical staining**

Immunohistochemical staining of ER, PR, HER-2, and pS6K1 was used to evaluate expression status and had been routinely performed for each patient on core needle biopsy specimens obtained during the diagnosis of primary breast cancer. Surgical specimens were used in cases where core needle biopsy specimens were unavailable. ER or PR positivity was defined as the expression of the ER or PR in at least 1% of tumor cells as shown by immunohistochemistry. The pS6K1 expression status was evaluated on a scale of 0 to 3+ by immunohistochemistry using the mouse monoclonal anti-pS6K1 antibody (Cell Signaling Technology, Danvers, USA; dilution 1:50). Details of the procedures are described in our previous report, which evaluated pS6K1 status in 304 hormone receptor-positive breast cancer patients [14]. Scores of 0 and from 1+ to 3+ were regarded as negative and positive pS6K1 expression, respectively.

**Statistical analysis**

Statistical analyses were performed using the $\chi^2$ and Fisher’s exact test to assess the correlation between pS6K1 expression and other clinicopathological parameters. The DFS of patients treated with AIs or SERMs was evaluated with respect to the pS6K1 status. DFS was defined as the time from diagnosis to the detection of any recurrence, contralateral breast cancer, secondary malignancy, or to death without recurrence. Survival curves were constructed using the Kaplan-Meier method. Differences in survival rates were assessed using the log-rank test. For univariate and multivariate analysis, the Cox proportional-hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). A $p$-value of < 0.05 was considered statistically significant.

**RESULTS**

**Patient characteristics**

Among the 428 patients analyzed, 244 (57.1%) and 184 (42.9%) patients had pS6K1 positive and negative tumors, respectively (Table 1). The 2 groups were well balanced on a number of patient characteristics, including age, N stage, hormone receptor status, histologic factors,
surgical treatment methods, and adjuvant endocrine therapy. BMI, an indicator of systemic adiposity, did not differ significantly between patients with a different pS6K1 status ($p = 0.526$). Analysis of patient risk factors according to pS6K1 and adjuvant endocrine therapy status are shown in Supplementary Table 1. AIs and SERMs were administered to 288 (67.3%) and 140 (32.7%) patients, respectively. Seventeen (4%) premenopausal patients underwent ovarian function suppression.

### Expression of pS6K1 and patient outcomes

During the median follow-up period of 44 months (range, 1–90), 43 cases of recurrence were observed, which included 12 and 33 locoregional recurrences and distant metastases, respectively. Secondary malignancies were observed in 4 patients. Only one death occurred in this cohort.

| Table 1. Patients characteristics |
|-----------------------------------|
| Characteristics                  | pS6K1 positive (n = 244) | pS6K1 negative (n = 184) | $p$-value |
| Age at diagnosis (yr)            |                         |                         | 0.898     |
| < 50                              | 77 (31.6)               | 57 (31.0)               |           |
| ≥ 50                              | 167 (68.4)              | 127 (69.0)              |           |
| Mass size (cm)                   |                         |                         | 0.066     |
| < 2                               | 112 (45.9)              | 101 (54.9)              |           |
| ≥ 2                               | 132 (54.1)              | 83 (45.1)               |           |
| BMI (kg/m$^2$)                   |                         |                         | 0.526     |
| < 25                              | 150 (61.7)              | 108 (58.7)              |           |
| ≥ 25                              | 93 (38.3)               | 76 (41.3)               |           |
| Node stage                       |                         |                         | 0.148     |
| N1                                | 199 (81.6)              | 159 (86.4)              |           |
| N2                                | 35 (14.3)               | 14 (7.6)                |           |
| N3                                | 10 (4.1)                | 11 (6.0)                |           |
| Stage                             |                         |                         | 0.438     |
| II                                | 157 (64.3)              | 125 (67.9)              |           |
| III                               | 87 (35.7)               | 59 (32.1)               |           |
| Progesterone receptor             |                         |                         | 0.125     |
| Negative                          | 79 (32.4)               | 47 (25.5)               |           |
| Positive                          | 165 (67.6)              | 137 (74.5)              |           |
| HER2                              |                         |                         | 0.075     |
| Negative                          | 201 (82.4)              | 163 (88.6)              |           |
| Positive                          | 43 (17.6)               | 21 (11.4)               |           |
| Histologic grade                  |                         |                         | 0.686     |
| G1                                | 53 (21.7)               | 42 (22.8)               |           |
| G2                                | 107 (43.9)              | 84 (45.7)               |           |
| G3                                | 59 (24.2)               | 37 (20.1)               |           |
| Unknown                           | 25 (10.2)               | 21 (11.4)               |           |
| Chemotherapy                      |                         |                         | 0.457     |
| None                              | 20 (8.2)                | 19 (10.3)               |           |
| Done                              | 224 (91.8)              | 165 (89.7)              |           |
| Surgery                           |                         |                         | 0.941     |
| BCS                               | 99 (40.6)               | 74 (40.2)               |           |
| TM                                | 145 (59.4)              | 110 (59.8)              |           |
| Radiotherapy                      |                         |                         | 0.349     |
| None                              | 77 (31.6)               | 66 (35.9)               |           |
| Done                              | 167 (68.4)              | 118 (64.1)              |           |
| Endocrine therapy                 |                         |                         | 0.649     |
| AI                                | 162 (66.4)              | 126 (68.5)              |           |
| SERM                              | 82 (33.6)               | 58 (31.5)               |           |

Values are presented as number of patients (%). pS6K1 = phosphorylated ribosomal S6 kinase 1; BMI = body mass index; HER2 = human epidermal growth factor receptor; TM = total mastectomy; BCS = breast conserving surgery; AI = aromatase inhibitor; SERM = selective estrogen receptor modulator.
In the pS6K1 positive group, DFS was significantly longer in patients treated with AIs than in those treated with SERMs (Figure 1A, \( p = 0.016 \)). The 5-year DFS rates were 83.5% and 50.7% for the AI and SERM group, respectively. In contrast, in patients with pS6K1 negative tumors, there was no significant difference in DFS between the groups treated with AIs or SERMs (Figure 1B, 5-year DFS 87.6% vs. 91.4%, \( p = 0.630 \)). The five-year DFS rates were 75.7% and 88.6% for pS6K1 positive and negative patients, respectively (HR, 0.43; 95% CI, 0.23–0.82, \( p = 0.010 \)).

On univariate analysis, AI therapy, as well as PR and HER-2 expression, were significantly associated with better DFS in the pS6K1 positive group. In the pS6K1 negative group, tumor size, stage, as well as PR and HER-2 overexpression were significantly associated with better prognosis (Table 2). Variables that were significant in the univariate analysis were examined on the multivariate analysis according to pS6K1 status. On multivariate analysis, AI therapy remained a significant predictor of better DFS in patients with a positive pS6K1 expression status (HR, 0.37; 95% CI, 0.18–0.78, \( p = 0.008 \), Table 2). In contrast, DFS was not affected by the type of endocrine therapy in pS6K1 negative patients (HR, 1.37; 95% CI, 0.38–4.91; \( p = 0.632 \)). We performed a subgroup analysis according to age, as younger patients (age < 50) may have received SERMs more frequently than AIs, due to the unique reimbursement system of our country (Supplementary Table 1). The Kaplan-Meier estimates in patients with ages < 50 showed improved DFS in patients with pS6K1 positive tumors treated with AIs than in those treated with SERMs (\( p = 0.021 \), Supplementary Figure 1A). In patients with ages ≥ 50, the difference in DFS was not statistically significant. However, it seemed that patients with pS6K1 positive tumors had better outcomes when treated with AIs than with SERMs (HR, 0.48; 95% CI, 0.16–1.44; \( p = 0.188 \), Figure 1C).

DISCUSSION

In this study, we found that AI therapy was associated with better DFS in patients with pS6K1 positive tumors, when compared to SERM therapy. To the best of our knowledge, this is the first study to evaluate pS6K1 expression status as a potential predictive marker for adjuvant AI therapy benefits in postmenopausal women.

Figure 1. Kaplan-Meier DFS curves for adjuvant AIs and SERMs in patients with (A) positive pS6K1 expression status and (B) negative pS6K1 expression status. Patients with positive pS6K1 expression status showed better DFS when treated with AIs than with SERM (\( p = 0.016 \)). However, in pS6K1 negative patients, there was no difference in DFS between AIs and SERMs (\( p = 0.630 \)).

DFS = disease-free survival; AI = aromatase inhibitor; SERM = selective estrogen receptor modulator; pS6K1 = phosphorylated ribosomal S6 kinase 1.
Table 2. Univariate and multivariate analyses of DFS based on pS6K1 status using Cox proportional hazard regression

| Variables          | Events (n = 29) | 5-year survival (%) | Univariate analysis | Multivariate analysis |
|--------------------|-----------------|----------------------|---------------------|----------------------|
|                    |                 |                      | HR (95% CI)         | p-value              |
|                    |                 |                      |                     | HR (95% CI)         | p-value              |
| pS6K1 positive     |                 |                      |                     |                     |                     |
| Age (yr)           |                 |                      |                     |                     |                     |
| ≤ 50               | 10              | 71.5                 | 0.91 (0.43–1.93)    | 0.809                |
| > 50               | 19              | 78.7                 | -                   | -                    |
| BMI (kg/m²)        |                 |                      |                     |                     |                     |
| ≤ 25               | 10              | 82.8                 | 1.07 (0.51–2.22)    | 0.862                |
| > 25               | 19              | 70.8                 | -                   | -                    |
| Size of tumor (cm) |                 |                      |                     |                     |                     |
| ≤ 2                | 11              | 78.4                 | 1.60 (0.78–3.30)    | 0.204                |
| > 2                | 18              | 73.4                 | -                   | -                    |
| Node stage         |                 |                      |                     |                     |                     |
| N1                 | 22              | 76.8                 | 1.29 (0.55–2.99)    | 0.557                |
| N2                 | 4               | 83.9                 | -                   | -                    |
| N3                 | 3               | 45.0                 | -                   | -                    |
| PR                 |                 |                      |                     |                     |                     |
| Negative           | 13              | 56.8                 | 2.08 (1.01–4.27)    | 0.047                |
| Positive           | 16              | 81.7                 | 2.24 (1.08–4.64)    | 0.030                |
| HER2               |                 |                      |                     |                     |                     |
| Negative           | 19              | 78.0                 | 0.43 (0.20–0.90)    | 0.025                |
| Positive           | 10              | 64.2                 | 0.40 (0.19–0.84)    | 0.016                |
| Histologic grade   |                 |                      |                     |                     |                     |
| G1or G2            | 18              | 71.7                 | 1.36 (0.94–1.99)    | 0.105                |
| G3                 | 11              | 70.3                 | -                   | -                    |
| Unknown            | 1               | 75.0                 | -                   | -                    |
| Chemotherapy       |                 |                      |                     |                     |                     |
| None               | 1               | 94.1                 | 0.87 (0.12–6.49)    | 0.894                |
| Done               | 28              | 75.4                 | -                   | -                    |
| Endocrine therapy  |                 |                      |                     |                     |                     |
| AI                 | 16              | 83.5                 | 0.44 (0.21–0.87)    | 0.019                |
| SERM               | 13              | 50.7                 | 0.37 (0.18–0.78)    | 0.008                |
| pS6K1 negative     |                 |                      |                     |                     |                     |
| Age (yr)           |                 |                      |                     |                     |                     |
| ≤ 50               | 3               | 89.6                 | 0.61 (0.17–2.19)    | 0.448                |
| > 50               | 11              | 88.1                 | -                   | -                    |
| BMI (kg/m²)        |                 |                      |                     |                     |                     |
| ≤ 25               | 4               | 90.4                 | 0.54 (0.17–1.71)    | 0.293                |
| > 25               | 10              | 87.4                 | -                   | -                    |
| Size of tumor (cm) |                 |                      |                     |                     |                     |
| ≤ 2                | 3               | 95.7                 | 4.89 (1.36–17.53)   | 0.015                |
| > 2                | 11              | 80.1                 | 4.32 (1.20–15.53)   | 0.025                |
| Node stage         |                 |                      |                     |                     |                     |
| N1                 | 11              | 88.8                 | 1.65 (0.37–7.39)    | 0.514                |
| N2                 | 3               | 81.1                 | -                   | -                    |
| N3                 | 0               | 100                  | -                   | -                    |
| PR                 |                 |                      |                     |                     |                     |
| Negative           | 8               | 77.1                 | 3.90 (1.35–11.25)   | 0.012                |
| Positive           | 6               | 92.6                 | 2.97 (1.01–8.72)    | 0.048                |
| HER2               |                 |                      |                     |                     |                     |
| Negative           | 9               | 91.3                 | 0.30 (0.10–0.88)    | 0.029                |
| Positive           | 5               | 72.6                 | 0.38 (0.13–1.16)    | 0.089                |
| Histologic grade   |                 |                      |                     |                     |                     |
| G1or G2            | 9               | 89.1                 | 1.32 (0.72–2.40)    | 0.372                |
| G3                 | 4               | 85.6                 | -                   | -                    |
| Unknown            | 1               | 89.2                 | -                   | -                    |
| Chemotherapy       |                 |                      |                     |                     |                     |
| None               | 2               | 74.1                 | 3.0 (0.67–13.44)    | 0.152                |
| Done               | 12              | 89.5                 | -                   | -                    |
| Endocrine therapy  |                 |                      |                     |                     |                     |
| AI                 | 11              | 87.6                 | 1.37 (0.38–4.91)    | 0.632                |
| SERM               | 3               | 91.4                 | -                   | -                    |

DFS = disease-free survival; pS6K1 = phosphorylated ribosomal S6 kinase 1; HR = hazard ratio; CI = confidence interval; BMI = body mass index; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; AI = aromatase inhibitor; SERM = selective estrogen receptor modulator.
The exact mechanism for the difference in prognosis between groups with different pS6K1 expression status is not yet fully understood. However, we suggest that the connection between adipogenesis, local estradiol levels, and the prognosis of hormone-sensitive breast cancer may help explain the predictive role of pS6K1 in postmenopausal women. Presumptively, the microenvironment of tumors expressing pS6K1 may have higher local estradiol levels than that of tumors not expressing pS6K1. As such, we suggest that pS6K1 may predict adjuvant AI therapy benefits in postmenopausal women. However, our results indicated that the pS6K1 expression status could be a more effective predictor in patients with ages < 50 than patients with ages ≥ 50.

The adipose tissue is a dynamic component of the endocrine system, wherein mature adipocytes occupy 90% of the volume, while adipocyte precursor cells become mature adipocytes through an interactive two-step process called adipogenesis. A precursor adipose stem cell differentiates into a preadipocyte (early adipogenesis) and then undergoes terminal differentiation to become a mature adipocyte (late adipogenesis). The mTOR pathway and its effector pS6K1, appear to be critical mediators in the development of obesity, defined as an excess of adipose tissue, and of adipogenesis [9-11].

In postmenopausal patients with hormone-sensitive breast cancer, obesity remains a definite risk factor for poorer outcomes. The epidemiological link between obesity and hormone-sensitive breast cancer is well established [15-17]. However, the molecular links between adipogenesis and breast cancer are not completely understood. A small number of the preclinical studies investigating the relationship between adipogenesis and local estradiol levels in the breast cancer microenvironment have suggested that the development of breast cancer might cause alterations in adipocyte differentiation in the breast [18]. Changes in adipogenesis may induce modifications of the aromatase promoters and thereby could increase local estrogen production [19,20]. Others have reported that cytokines involved in adipogenesis may contribute to estradiol elevation by increasing aromatase expression and upregulating the ER in adipocytes and cancer cells [21,22]. Because the oncogenic effect of estradiol on the ER is mediated via the PI3K/AKT/mTOR pathway in hormone-sensitive breast cancer [23,24], increased pS6K1 levels might be representative of the active adipogenesis–breast cancer interaction. To the best of our knowledge, no studies have directly examined the relationship between pS6K1 expression and local tissue estrogen levels; such studies may have helped to confirm our hypothesis. However, in our cohort, there was no correlation between the expression status of pS6K1 and BMI ($p = 0.550$), a representative of systemic adiposity, which supports our hypothesis.

In clinical trials, estradiol depletion therapy with AIs has shown improved mortality and recurrence rates [25,26]. However, artificial depletion of body circulating estrogens may simultaneously produce adverse effects that may lead to early discontinuation of the treatment. Despite excellent survival outcomes, the discontinuation rate of AIs ranges between 30%–70% and is largely dependent on the presence and severity of the adverse effects [27]. Moreover, symptoms responsible for discontinuation of the initial AI also lead to cessation of the second AI in nearly 80% of patients [28]. Because insufficient treatment duration is detrimental to survival outcomes, a SERM may be an alternative option in patients with AI-related concerns [4,29].

SERMs have shown similar potential as AIs in selected low-risk patients. A study analyzing prognostic risks in the patient cohorts of the Breast International Group (BIG) 1-98 trial found
that a composite measure of typical low risk factors such as old age, negative lymph node status, tumor size \(<\) 2 cm, low tumor grade, HER-2 negative, and strong ER positivity predicts equivalent benefits from monotherapy with either letrozole or tamoxifen \([30]\). However, in most breast cancer patients, maximizing the survival benefits of adjuvant endocrine therapy while avoiding unwanted side effects, remains a dilemma. As such, the optimal treatment of these patients may be guided by the pS6K1 expression status. For instance, when adverse effects become an issue in endocrine therapy, AIs may be encouraged in postmenopausal patients with pS6K1 positive, hormone-sensitive tumors. Similarly, SERMs could be a more attractive alternative option in patients with pS6K1 negative tumors.

In our previous study, we showed that pS6K1 is a prognostic marker for poorer DFS in hormone-sensitive breast cancer patients \([14]\). The results of the current study revealed that the poorer prognosis of patients with pS6K1 positive tumors may be improved by using AIs providing estradiol depletion. Individual pS6K1 expression status evaluated by immunohistochemistry with readily available antibodies may serve as a simple and affordable predictive marker to select patients for AI therapy in the clinic.

The limitation of this study is that it was a single center-based retrospective study. Similarly, our results may be biased as the study did not include a matched cohort and hormonal treatment decision based on our unique reimbursement system may have contributed to the difference in results obtained for different age groups. Therefore, further prospective studies are needed to determine whether the results of our study could be applied to other populations. A median follow-up period of 44 months may be relatively short for hormone-sensitive breast cancer when considering cases of late recurrences. This was why only patients with node-positive disease were included in this study. In the adjuvant setting, a relatively large number of patients and a longer follow-up period would be necessary to show the differences in survival rates in a cohort of low-risk patients with endocrine sensitive disease. We plan to analyze long-term follow-up results, including those of patients with node-negative disease, in the future. Although the precise details of the underlying mechanisms need to be unraveled, elucidation of the function of pS6K1 in the estrogen-regulated pathway in association with adipogenesis may help predict patients that would derive greater benefit from AI therapy.

As such, positive pS6K1 expression was associated with better DFS in postmenopausal and ovarian function-suppressed patients with hormone-sensitive breast cancer treated with AIs than in those treated with SERMs. This indicates that pS6K1 expression status may be used as a predictive marker for adjuvant endocrine therapy in selected patients.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
Patient characteristics according to pS6K1 status and other risk factors

Click here to view

**Supplementary Figure 1**
Kaplan-Meier estimates of DFS according to age and pS6K1 expression status.

Click here to view
REFERENCES

1. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.

2. Brodie AM, Njar VC. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 1998;66:140.

3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60-2.

4. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:310-20.

5. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 2006;192:496-8.

6. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013;138:185-91.

7. van der Hage JA, van den Broek LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 2004;90:1543-50.

8. Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000;92:1252-9.

9. Yi SA, Han J, Han JW. Epigenetic role of nuclear S6K1 in early adipogenesis. BMB Rep 2016;49:401-2.

10. Yi SA, Um SH, Lee J, Yoo JH, Bang SY, Park EK, et al. S6K1 phosphorylation of H2B mediates EZH2 trimethylation of H3: a determinant of early adipogenesis. Mol Cell 2016;62:443-52.

11. Carnevali LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, et al. S6K1 plays a critical role in early adipocyte differentiation. Dev Cell 2010;18:763-74.

12. Bulun SE, Chen D, Moy J, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012;23:83-9.

13. Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009;150:2537-42.

14. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JL, et al. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 2011;126:93-9.

15. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014;25:1901-14.

16. Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 2016;34:4203-16.

17. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-8.
18. Pino F, La Noce M, Di Nucci D, Nicoletti GF, Salzillo R, De Rosa A, et al. Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: implication for autologous fat grafting. Cell Death Dis 2017;8:e2568.

19. Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 1997;61:175-84.

20. Zhao H, Zhou L, Shangguan AJ, Bulun SE. Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol 2016;57:R19-33.

21. Jiang N, Li Y, Shu T, Wang J. Cytokines and inflammation in adipogenesis: an updated review. Front Med 2019;13:314-29.

22. Weichhaus M, Broom I, Bermano G. The molecular contribution of TNF-α in the link between obesity and breast cancer. Onkol Rep 2011;25:477-83.

23. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92.

24. Azim HA, Kassem L, Treilleux I, Wang Q, El Enein MA, Anis SE, et al. Analysis of PI3K/mTOR pathway biomarkers and their prognostic value in women with hormone receptor-positive, HER2-negative early breast cancer. Transl Oncol 2016;9:114-23.

25. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41.

26. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.

27. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459-78.

28. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936-42.

29. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.

30. Viale G, Regan MM, Dell’Orto P, Mastropaques MG, Maiorano E, Rasmussen BB, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011;22:2204-7.